NCT02386813已完成不适用
International Extranodal NK/T-cell Lymphoma Project: Prognostic Factors in the Era of Nonanthracycline-based Treatment
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 770
- 试验地点
- 1
- 主要终点
- Overall survival
研究概览
简要总结
This study is to explore risk factors for poor progression-free survival (PFS) and overall survival (OS) in ENKTL, and establish a prognostic model for ENKTL patients treated with non-anthracycline based treatment.
详细描述
This is a retrospective cohort study using anonymized information from patients with ENKTL. The following criteria are required: (1) Patients diagnosed with ENKTL, nasal type between January 1, 1995 and December 31, 2014; (2) Patients treated with non-anthracycline based therapy as an initial treatment. The pathology of initial diagnosis was reviewed by designated pathologists.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients diagnosed with ENKTL, nasal type
- •Patients diagnosed between January 1, 1995 and December 31, 2014
- •Patients treated with nonanthracycline-based therapy as the initial treatment after diagnosis
- •Nonanthracycline-based therapy includes the following treatments:
- •Radiotherapy including concurrent chemoradiation
- •Chemotherapy not including anthracycline such as doxorubicin (e.g. SMILE, VIPD) The type of salvage treatment will not be a criterion for exclusion. Thus, patients who had received various kinds of salvage treatment including anthracycline-containing regimens can be included. Patients who had undergone autologous or allogeneic stem cell transplantation can also be included in the analysis if they satisfy the above-mentioned inclusion criteria.
排除标准
- •Patients who had received anthracycline-based therapy, such as CHOP or CHOP-like regimens, as the initial treatment.
- •Patients who do not have pathology slides available for central review.
结局指标
主要结局
Overall survival
时间窗: 5 year
Time between the date of diagnosis and any kinds of death
次要结局
- Progression-free survival(5 year)
研究者
Won Seog Kim
Professor
Samsung Medical Center
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Prognostic Nomogram of Extranodal NK/T-cell LymphomaExtranodal NK/T-cell LymphomaNCT04554511Sun Yat-sen University1,000
尚未招募
2 期
Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) in the Treatment of Untreated Early Non-upper Respiratory Tract or Advanced Extranodal NK/T-cell LymphomaNK-T-Cell Lymphoma, ExtranodalNCT05774028The First Affiliated Hospital with Nanjing Medical University50
Unknown
不适用
Prognosis Factors in Patients With Primary Central Nervous System LymphomaSurvival AnalysisPCNSLNCT05167630Zhengzhou University40
终止
不适用
A Study to Assess the Survival of Non-small Cell Lung Cancer Patients Treated With Tarceva After Failed Chemotherapy TreatmentNon-Squamous Non-Small Cell Lung CancerNCT01990261Hoffmann-La Roche33
已完成
不适用
Prognostic factors of non-small cell lung cancer patients with brain metastasison-small cell lung cancerJPRN-UMIN000030313KKR Sapporo Medical Center300